Cellanome vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cellanome is building a multi-omics platform combining genome sequencing, microfluidics, and integrated sensors to measure biological data at single-cell resolution; raised $100M Series A in 2023;
About
Cellanome is a biotechnology tools company founded in 2021 and headquartered in Menlo Park, California. The company is developing a next-generation multi-omics platform designed to simultaneously measure multiple layers of biological information — including genomics, transcriptomics, and proteomics — at single-cell resolution and at unprecedented scale. Its platform integrates genome sequencing, microfluidics, and proprietary integrated sensors to capture a more complete molecular portrait of individual cells than any existing single-omics technology can achieve alone.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.